We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Enamine Announces Extension of Collaboration with Sanofi in Early Drug Discovery

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enamine Announces Extension of Collaboration with Sanofi in Early Drug Discovery"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Enamine Ltd has announced that it has extended its collaboration agreement with Sanofi, an integrated global healthcare leader. Based on the success of the collaboration to date, the extension enables Sanofi to continue to access Enamine’s in-house designed and synthesized screening compound library, and select a library subset of novel drug-like screening compounds, according to Sanofi’s research needs.

Enamine’s library, which is now the industry’s most extensive range with 2,000,000 compounds, provides Sanofi with an optimal starting point for hit finding activities for multiple therapeutic targets and will be used at Sanofi’s worldwide screening facilities.

Michael Bossert, Head of Strategic Alliances at Enamine, commented: “We have worked with Sanofi since 2012 and are delighted to continue our agreement. At Enamine our focus is on the development of original and unique chemistry, and this extension reflects our scientific knowledge and ability to exceed partner expectations. The collaboration involves regular communication with Sanofi teams and is focused on facilitating the creation of new research projects to support the emergence of effective treatments for diseases.”